论文部分内容阅读
60岁以上的急性淋巴细胞白血病病人疗效常不及儿童和成年人,其长期存活率只有4％～15％。本文报告了作者14年来对影响老年急性淋巴细胞白血病预后因素的研究结果。 病人共46例,男性占54％,女性占46％,年龄60～87岁,中位年龄67岁。分为两组,ALL-2组选用阿霉素第8、29、43天用,强的松(PDN)第1～28天,然后减量,长春新碱(VCR)第1、8、15、29天,部分病例化疗结束后用1次大剂量阿糖胞苷,病人获完全缓解(CR)后巩固治疗1～4个月,然后维持治疗3年。ALL-3组柔红霉素1～3天,环磷酰胺(CTX)1、8天,VCR第1、8、14、21天,PDN 1～28天后减量,病人CR后给予1个疗程大
The efficacy of acute lymphoblastic leukemia patients over 60 years of age is often less than that of children and adults, and their long-term survival rate is only 4% to 15%. This article reports the results of the author’s 14-year study of the prognostic factors affecting acute lymphoblastic leukemia in the elderly. A total of 46 patients were male, 54% male, 46% female, aged 60 to 87 years, median age 67 years. Divided into two groups, ALL-2 group used doxorubicin for 8, 29, and 43 days, prednisone (PDN) for 1 to 28 days, and then reduced, vincristine (VCR) 1, 8, and 15 29 days, after the end of chemotherapy in some cases with a large dose of cytarabine, the patient received complete remission (CR) consolidation therapy for 1 to 4 months, and then maintain treatment for 3 years. ALL-3 group of daunorubicin 1 to 3 days, cyclophosphamide (CTX) 1 and 8 days, VCR 1, 8, 14, 21 days, PDN 1 to 28 days after the reduction, patients after CR given a course of treatment Big